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Background
Host defence peptide (HDP) has multiple properties [1,2]
potentiating it as a novel anticancer agent. However disad-
vantages include systemic toxicity [3]. To address this, a
prodrug was developed and the aim was to assess toxicity
differentials between this prodrug and its active peptide
component on T84 colonic carcinoma cells. Prodrug
bio activation mechanism was also assessed by use of a
Cathepsin B inhibitor.
Methods
Two peptides were provided: Gly-D-P18 and its prodrug
form. The prodrug, containing a linker which will serve as
substrate for a tumour associated protease, Cathepsin B,
and activate the drug. T84 cell lines were cultured sepa-
rately with Gly-D-P18 and its pro drug at concentrations
of 1 µM and 10 µM over 24 hours. Effects were evaluated
by LDH assay, Transepithelial resistance and Electrophy-
siological measurements. Cathepsin B inhibitor was also
incubated, at concentration of 10 µM, 1 µM, 200 nM, and
4nM with pro drug on T84 cells over 24 hours and their
effects assessed by transepithelial resistance and LDH
measurement.
Results
Pro drug caused a drop to 74.45% of initial resistance for
1 µM (n=5) and 22.56% for 10 µM (n=5) concentrations,
in comparison to Gly-D-P18 with 52.33% (n=5) and
21.676% (n=5) respectively. Also, the use of 10 µM pro-
drug with Cathepsin B inhibitor at 10 µM (n=3), 1 µM
(n=3), 200 nM (n=3), 4 nM (n=3) concentrations resulted
in a drops to 34.12%, 26.974%, 30.009%, 25.977% of initial
resistance respectively, compared to 26.804% of initial
resistance from standalone prodrug (n=3) treatment. No
effects were seen with regards to LDH release or chloride
secretion.
Conclusions
While the prodrug had comparatively decreased resistance
drop, inconclusive results and limitations indicated need
for further experimentation. In future, one could include
usage of wider range of viability tests and comparisons
against treatment with prodrug with uncleavable linkers as
well as on healthy cells.
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